Neurocrine Biosciences Inc (NBIX)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	—	—	—	169,500	0	0	169,000	377,700	335,100	330,700	326,300	322,000	317,900	425,000	419,500	414,100	408,807	403,589	398,466	393,435
Total assets	US$ in thousands	3,251,400	2,848,200	2,613,100	2,359,800	2,368,700	2,143,400	2,005,700	2,144,500	2,072,500	2,017,300	1,956,400	1,846,400	1,734,700	1,502,600	1,515,600	1,361,900	1,306,000	1,179,940	1,066,860	957,723
Debt-to-assets ratio		0.00	0.00	0.00	0.07	0.00	0.00	0.08	0.18	0.16	0.16	0.17	0.17	0.18	0.28	0.28	0.30	0.31	0.34	0.37	0.41

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $3,251,400K
= 0.00

The debt-to-assets ratio of Neurocrine Biosciences, Inc. has been consistently low over the past eight quarters, ranging from 0.05 to 0.18. A low debt-to-assets ratio indicates that the company has a relatively low level of debt compared to its total assets.

The gradual increase in the ratio from Q1 2022 to Q1 2023 suggests a slight increase in the company's debt relative to its asset base during this period. However, the ratio remains at a relatively low level, indicating that Neurocrine Biosciences, Inc. has been managing its debt levels prudently.

Overall, the trend in the debt-to-assets ratio reflects a conservative approach to managing debt and indicates that the company has a strong financial position with a lower reliance on debt financing to support its operations and investments.